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Background: Reorganisation of clinical follow-up care in England was proposed by the National Cancer Survivorship Initiative
(NCSI), based on cancer type and treatment, ranging from Level 1 (supported self-management) to Level 3 (consultant-led care).
The objective of this study was to provide an investigation of the risks of serious adverse health-outcomes associated with NCSI
Levels of clinical care using a large population-based cohort of childhood cancer survivors.
Methods: The British Childhood Cancer Survivor Study (BCCSS) was used to investigate risks of specific causes of death,
subsequent primary neoplasms (SPNs) and non-fatal non-neoplastic outcomes by NCSI Level.
Results: Cumulative (excess) risks of specified adverse outcomes by 45 years from diagnosis among non-leukaemic survivors
assigned to NCSI Levels 1, 2 and 3 were for: SPNs—5% (two-fold expected), 14% (four-fold expected) and 21% (eight-fold
expected); non-neoplastic death—2% (two-fold expected), 4% (three-fold expected) and 8% (seven-fold expected); non-fatal non-
neoplastic condition—14%, 27% and 40%, respectively. Consequently overall cumulative risks of any adverse health outcome were
21%, 45% and 69%, respectively.
Conclusions: Despite its simplicity the risk stratification tool provides clear and strong discrimination between survivors assigned
to different NCSI Levels in terms of long-term cumulative and excess risks of serious adverse outcomes.
Comprehensive reorganisation of clinical follow-up care for cancer
survivors was proposed by the National Cancer Survivorship
Initiative (NCSI) throughout the National Health Service (NHS) in
England (NHS Improvement, 2011a, b; Glaser et al, 2013). A prior
investigation into the follow-up practices in Children’s Cancer and
Leukaemia Group (CCLG) Centres indicated wide variations in the
proportion of childhood cancer survivors under hospital follow-up
beyond 5 years from diagnosis (Taylor et al, 2004). The NCSI and
the Independent Cancer Taskforce proposed that the level of
clinical follow-up care offered to each survivor should be evidence-
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based and correspond to their risk of serious adverse health
outcomes (NHS Improvement, 2011a, b; Glaser et al, 2013;
Independent Cancer Taskforce, 2015). The NCSI proposed a
system of risk stratification principally based on cancer type and
treatment received and ranges from Level 1 (supported self-
management) to Level 3 (multidisciplinary consultant-led clinical
care) (NHS Improvement, 2011a, b; Glaser et al, 2013). It is a
development of our previously proposed methodology for stratify-
ing survivors into three levels of clinical follow-up care (Wallace
et al, 2001). So far, there have only been a few small-scale studies
assessing the risks of adverse health outcomes associated with
using this risk stratification tool, which in aggregate relate to just
over 900 survivors (Absolom et al, 2006; Eiser et al, 2006; Michel
et al, 2009; Edgar et al, 2013).
This NCSI risk stratification tool presented here is simple and
does not require detailed information on cumulative doses
of individual cytotoxic drugs or radiation doses to major
organs. This has considerable advantages as such details
may not be readily available, particularly if treatments were given
decades ago.
Levels 1 and 2 of clinical care proposed by the NCSI
have substantially lower frequencies of hospital attendance
compared with Level 3. It is essential to investigate whether
individuals proposed to be followed-up at Levels 1 or 2 experience
an increased risk of serious adverse health-outcomes, which could
potentially be avoided, or ameliorated, with appropriate hospital
follow-up.
There is a pressing need to reliably quantify the overall risks of
adverse health-outcomes associated with the NCSI system of risk
stratification, formally introduced in 2011 (NHS Improvement,
2011a, b), because it is in increasingly widespread use in the NHS
for childhood cancer survivors. Such usage results from the
widespread participation of CCLG Centres in the development
work of the NCSI. Data from the British Childhood Cancer
Survivor Study (BCCSS) provide an unrivalled opportunity to
reliably estimate these risks, as there has been no previous large-
scale investigation of the serious health risks associated with the
NCSI Levels of care in the long-term, and to the best of our
knowledge this is the first risk stratification tool that has been
proposed for general clinical use for childhood cancer survivors.
We provide a large-scale population-based investigation of the
risks of serious adverse health-outcomes associated with the NCSI
Levels of clinical care up to 45 years from diagnosis using data
from the BCCSS.
MATERIALS AND METHODS
Sources of data
1. The BCCSS population-based cohort was used to assess the
risks of specific causes of death and subsequent
primary neoplasms (SPNs). The BCCSS cohort consists of
17 981 individuals who were diagnosed with cancer,
when aged 0–14 years inclusive, between 1940 and 1991, in
Britain, and who survived at least 5 years. Information on
exposure to initial radiotherapy and chemotherapy was
available for the entire cohort in the form YES/NO/NO
RECORD. Further details including objectives, methods and
response rates are available elsewhere (Hawkins et al, 2008).
Approval for the study was obtained from the appropriate
Research Ethics Committees and the Confidentiality Advisory
Group consented to processing identified data without indivi-
dual patient consent.
2. Between 2001 and 2006 a questionnaire addressing adverse health
and social outcomes was sent to those 14 836 BCCSS survivors
who were aged at least 16 years via their primary care physician
(for the questionnaire see: http://www.birmingham.ac.uk/
research/activity/mds/projects/HaPS/PHEB/CCCSS/bccss/docum
ents.aspx). In total 10 483 (71%) questionnaires were completed
and returned by December 31, 2006. These questionnaires were
used to assess risks of specific non-fatal non-neoplastic adverse
health-outcomes. We focused on physical conditions graded 3 or
4 using the Common Terminology Criteria for Adverse Events
(CTCAE) version 3 (Cancer Therapy Evaluation Programme,
2006). Such conditions are considered severe, life threatening or
disabling.
3. Records of 2844 individuals included within the BCCSS who
were treated within one of the national Medical Research
Council (MRC) randomised trials into treatment of acute
lymphoblastic leukaemia (ALL) were used to investigate risks of
adverse health outcomes in relation to treatment received, based
on the assumption that treatment was delivered, as prescribed in
protocol.
Risk stratification. The NCSI clinical Levels of care are described
in Figure 1A (further details in Supplementary Appendix 1). For
the purposes of the present investigation risk stratification, based
on childhood cancer type and its treatment, was undertaken as
described in Figure 1B for all childhood cancers except leukaemia
and for individuals who were diagnosed with ALL and treated
within an MRC trial, as described in Figure 1C.
Ascertainment and grading of adverse health events. Ascertain-
ment of causes of deaths and incident SPNs within the BCCSS was
entirely population-based and achieved by individual patient
electronic record linkage via the NHS Information Centre. For
each death, we obtained the death certificate and underlying cause
of death as coded by the Office for National Statistics. Potential
SPNs were confirmed by reviewing relevant diagnostic reports,
particularly histopathology reports. Further details are available in
our most recent detailed investigations of causes of death
(Reulen et al, 2010; Fidler et al, 2016) and SPNs (Reulen et al,
2011) in our cohort.
Occurrence of non-fatal non-neoplastic adverse health-out-
comes were ascertained through the BCCSS questionnaire. Each
non-fatal non-neoplastic condition was graded using the CTCAE
version 3 (Cancer Therapy Evaluation Programme, 2006) by three
authors ERL and DLW in collaboration with KCO of the North
American Childhood Cancer Survivor Study (CCSS) to ensure
comparability with the CCSS. This version of the CTCAE (Cancer
Therapy Evaluation Programme, 2006) was used because all related
published studies used this version and such standardisation
facilitates making satisfactory comparisons. Only events graded 3
or 4 were included here. In addition to indicating the condition, the
survivor provided the diagnosis date/age. Potentially treatment-
related non-fatal non-neoplastic events were grouped into 10
specific categories as defined by the CTCAE (vision; hearing;
speech; circulatory; pulmonary; gastrointestinal; renal; musculos-
keletal; neurological; endocrine), plus an overall category for any of
these events.
Statistical methods. Risks of three outcomes were investigated:
SPNs; fatal non-neoplastic conditions; non-fatal non-neoplastic
conditions. Time at risk for each of these outcomes began at five
years subsequent to first primary neoplasm (FPN) diagnosis.
End of period of risk depended on the adverse outcome
being analysed. For SPNs/specific fatal non-neoplastic conditions,
exit from risk was the date associated with the first of the
following events: diagnosis of a SPN/death from specific cause,
loss to follow-up, death from other cause or study end-date (the
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median questionnaire completion date). For non-fatal
non-neoplastic conditions, exit from risk was the date of
diagnosis of the condition, otherwise the questionnaire
completion date.
Survivors were stratified according to their NCSI Levels of
clinical care and the cumulative incidence by period of follow-up
from diagnosis for each adverse health outcome was estimated. For
the estimation of cumulative incidence of a SPN and specific fatal
non-neoplastic conditions, other deaths were treated as competing
risks (Gooley et al, 1999; Coviello and Bogges, 2004). For non-fatal
non-neoplastic conditions, the complement of the Kaplan–Meier
estimate (1-KM) was used to estimate the cumulative risk. Log
rank tests were used to investigate for heterogeneity and trend in
cumulative risk.
Standardised incidence ratios (SIRs) and standardised
mortality ratios (SMRs) were calculated as the ratio of
observed (O) to expected (E) numbers of relevant events (O/E).
Expected numbers were estimated by accumulating person
years at risk within specific gender and five-year age and one-
year calendar period strata and multiplying by gender, age and
calendar period specific neoplasm and death rates in the general
population of England and Wales. Poisson regression was used to
test for heterogeneity and linear trend in SIRs and SMRs across
NCSI Levels.
All analyses were carried out using Stata statistical software
(version 13; Stata Corp., College Station, TX, USA). Statistical
significance was taken at the 5% level, with two-sided tests.
RESULTS
Risks after all childhood cancers except leukaemia
Risk of subsequent primary neoplasms. Observed cumulative
risks (95% CI) by 45 years from diagnosis among survivors
assigned to Levels 1, 2 and 3 were 5% (95% CI: 3–7%), 14%
(12–17%) and 21% (18–24%), respectively (test for trend
Po0.0001) (Figure 2A). Corresponding SIRs (95% CI) were 2
(1.6–2.8), 4 (3.6–4.7) and 8-fold expected (7.5–9.1), respectively
(test for trend Po0.001). Cumulative risks and SIRs were
estimated for all SPNs excluding non-melanoma skin cancers
(NMSC) and non-glioma central nervous system neoplasms
(NGCNS) in Table 1, and gave broadly similar results.
Table 1 also gives the observed cumulative risks by 45 years
from diagnosis, and the corresponding SIRs, for specific types of
SPNs among survivors assigned to Levels 1, 2 and 3. For digestive,
bone, connective and soft tissue, breast and thyroid cancers and for
NMSC, glioma CNS neoplasm and NGCNS there was evidence
that the SIR increased with increased NCSI Level.
Type of childhood cancer 
Treatment HODG NHL CNS NEURO RETINO (HERITABLE) RETINO (NON-HERITABLE) WILMS BONE STS OTHER
S alone 1 1 2 1 2 1 1 1 1 1
R alone 3 2 3 2 3 2 2 2 2 2
C alone 2 2 2 2 2 1 2 2 2 2
S + R 3 2 3 2 3 2 2 2 2 2
S + C 2 2 2 2 2 1 2 2 2 2
R + C 3 2 3 3 3 2 3 3 3 2
S + R + C 3 2 3 3 3 2 3 3 3 2
S- surgery; R - Radiotherapy; C- Chemotherapy; HODG- Hodgkin's lymphoma;  NHL-  Non-Hodgkin's lymphoma; CNS - Central nervous system; NEURO - Neuroblastoma; RETINO- Retinoblastoma; STS - soft tissue sarcoma 
A
B
C
Characteristics may include:
Characteristics may include:
Characteristics may include:
No routine outpatient attendances
Self-care with support
and open access
Shared care
Complex case
management
through
MDT
Professional care
Needs stratification Int
er
ve
nti
on
Planned review of care e.g. hospital,
community, face to face or telephone
Complex rapidly changing health
Complex ongoing treatment regimes
Requiring regular MDT reviews
Other input required e.g. cardiology,
haematology, gastroenterology
Complex treatment complications or
symptomatic needs
Clinical examination if required
Patients with co-morbidities
Those who are unable/declined to
self manage
Information on prescription and/or an
educational intervention
Automated surveillance tests with results
by telephone or post
Ability to re-access system with/without
reference to GP
LEVEL 1
Potential model of care being tested
Level 3
Level 2
Level 1
LEVEL 2
LEVEL 3
Level 1 - no radiotherapy
Level 2 - cranial irradiation under 24 Gy
Level 3 - cranial irradiation over 24 Gy or treatment for relapse (including testicular)
or bone marrow transplantation for initial treatment.
Figure 1. NCSI Levels of follow-up care. (A) The NCSI clinical levels of care (NHS Improvement, 2011a). (B) NCSI Levels of clinical follow-up
defined in terms of type of childhood cancer and treatment received. Abbreviations: S¼ surgery; R¼Radiotherapy; C¼Chemotherapy;
HODG¼Hodgkin’s lymphoma; NHL¼Non-Hodgkin’s lymphoma; CNS¼Central Nervous System; NEURO¼Neuroblastoma;
RETINO¼Retinoblastoma; STS¼ soft tissue sarcoma. (C) NCSI Levels of clinical follow-up for ALL survivors. Note: There were insufficient survivors
of other specific types of leukaemia for meaningful analysis and therefore such survivors are not considered further within this study.
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Risk of fatal non-neoplastic conditions. Observed cumulative
risks (95% CI) by 45 years from diagnosis among survivors
assigned to Levels 1, 2 and 3 were 2% (95% CI: 1.1–4.4%), 4% (3.0–
5.7%) and 8% (6.3–10.5%), respectively (test for trend Po0.00005)
(Figure 2B). The corresponding SMRs (95% CI) were 2 (1.3–3.3), 3
(2.7–4.4) and 7-fold expected (5.9–8.3), respectively (test for trend
Po0.001).
Table 2 (upper half) gives the observed and expected numbers of
specific categories of non-neoplastic causes of death across
different NCSI Levels, together with the cumulative risks by 45
years from diagnosis. There was evidence of an increase in the
SMRs with increased NCSI Level from Level 1 to Level 3 for deaths
from circulatory, cerebrovascular, pulmonary and neurological
causes.
Among NCSI Level 1 survivors restricting attention to those causes
with more than five observed deaths, there was a five-fold excess of
deaths from pulmonary causes. Among NCSI Level 2 survivors,
restricting attention to those causes with more than five observed
deaths, there was a four-fold excess in the number of deaths observed
from cardiac, cerebrovascular, pulmonary and neurological causes.
Classification to NCSI Level (Figure 1B and C) used only limited
information in the BCCSS computer record, before accessing available
medical records. Detailed examination of the medical history of these
cases, reviewed by physicians, suggested that a greater degree of
routine follow-up would not have been helpful in preventing or
delaying the excess deaths (data not published due to the potentially
individually identifiable nature of the data).
Risk of non-fatal non-neoplastic conditions. Figure 2C provides
cumulative risks of a non-fatal non-neoplastic (CTCAE grade 3
or 4) condition corresponding to any of the 10 categories specified
above, among survivors assigned to the NCSI Levels. The most
common conditions diagnosed subsequent to 5-year survival were
cardiovascular (19%), endocrine (18%) and pulmonary (14%),
together accounting for 51% of all conditions diagnosed. By 45
years from diagnosis the cumulative risk (95% CI) of any
potentially treatment-related non-fatal non-neoplastic condition
for survivors assigned to NCSI Levels 1, 2 and 3 were 14% (95% CI:
10–19%), 27% (24–31%) and 40% (35–45%), respectively (test for
trend, Po0.00005).
Table 2 (lower half) gives the cumulative risks of specific
potentially treatment-related non-fatal non-neoplastic conditions
among survivors by NCSI Level. The cumulative risk of each
specific condition increased with increased NCSI Level (all
Po0.01), with the exception of gastrointestinal and musculoske-
letal conditions.
Risks after acute lymphoblastic leukaemia
Risk of SPNs. Figure 3A provides observed and expected cumulative
risks, with corresponding SIRs, of any SPN for survivors assigned to
NCSI Levels 2 and 3. Insufficient survivors were classified to Level 1
to reliably estimate risks. Observed cumulative risks (95% CI) by 20
years from diagnosis among survivors assigned to Levels 2 and 3
were 2% (95% CI: 1.4–3.8%) and 3% (2.0–4.3%), respectively
(P¼ 0.205). The corresponding SIRs (95% CI) were 6 (4.1–9.7) and
8-fold expected (6.2–11.3), respectively (P¼ 0.295). Exclusion of
NMSC and NGCNS had little impact.
Risk of fatal non-neoplastic conditions. Observed cumulative
risks (95% CI) by 20 years from diagnosis among survivors
assigned to Levels 2 and 3 were 0.1% (95% CI: 0.01–0.5%) and 1%
(0.5–1.7%), respectively (Po0.01) (Figure 3B). The corresponding
SMRs (95% CI) for Levels 2 and 3 were 1 (0.1–6.3) and 8-fold
expected (4.6–13.8), respectively (Po0.01).
Risk of non-fatal non-neoplastic conditions. By 20 years from
diagnosis the cumulative risk (95% CI) of any non-fatal non-
neoplastic condition for survivors assigned to Levels 2 and 3 were
4% (95% CI: 2.8–7.1%) and 9% (7.0–12.0%), respectively
(Po0.001) (Figure 3C).
Risk of SPNs, fatal and non-fatal non-neoplastic conditions
among survivors of specific types of cancer assigned to
particular NCSI Levels. For evidence-based long-term clinical
follow-up the most practically useful risk stratification information
relates to the risk of specific adverse outcomes among individuals
with a specified type of cancer and NCSI Level. Supplementary
Appendix 2 (Supplementary Table 1) provides cumulative and
excess risks by 25 years from diagnosis for survivors diagnosed
21.1%
14.3%
5.1%
4.6–5.1%
0
2
4
6
8
10
12
14
16
18
20
22
Cu
m
ul
at
ive
 in
cid
en
ce
 (%
)
5 10 15 20 25 30 35 40 45
Period of follow-up from diagnosis (years)
Level 1 - obs incl NMSC & NGCNS
Level 2 - obs incl NMSC & NGCNS
Level 3 - obs incl NMSC & NGCNS
Levels 1–3 - expected
SIR = 8.3 (7.5 to 9.1) 
SIR = 4.2 (3.6 to 4.7) 
SIR = 2.1 (1.6 to 2.8)
8.2%
4.2%
2.3%
1.7–2.1%
0
1
2
3
4
5
6
7
8
9
10
Cu
m
ul
at
ive
 in
cid
en
ce
 (%
)
5 10 15 20 25 30 35 40 45
Period of follow-up from diagnosis (years)
Level 1 - observed
Level 2 - observed
Level 3 - observed
Levels 1–3 - expected
SMR = 7.0 (5.9 to 8.3) 
SMR = 3.4 (2.7 to 4.4) 
SMR = 2.1 (1.3 to 3.3) 
39.9%
27.3%
13.8%
0
5
10
15
20
25
30
35
40
45
Cu
m
ul
at
ive
 in
cid
en
ce
 (%
)
5 10 15 20 25 30 35 40 45
Period of follow-up from diagnosis (years)
Level 1 - Observed
Level 2 - Observed
Level 3 - Observed
A
B
C
Figure 2. Risks of adverse health events after all childhood cancers
except leukaemia. (A) Observed and expected risks of any subsequent
primary neoplasm after all childhood cancers except leukaemia.
Abbreviations: incl¼ including; NGCNS¼Non-glioma central nervous
system tumours; NMSC¼non-melanoma skin cancer; obs¼observed.
The cross bars are 95% CI. Log-rank test for equality of observed risks
yields Po0.0001. (B) Observed and expected risks of any fatal non-
neoplastic event after all childhood cancers except leukaemia. Log-rank
test for equality of observed risks yields Po0.00005. (C) Observed risks
of any non-fatal non-neoplastic condition after all childhood cancers
except leukaemia. Log-rank test for equality of observed risks yields
Po0.00005.
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with each specific cancer type (except ALL) and assigned to a
particular NCSI Level for which there were at least 100 survivors
still at risk at 25 years after diagnosis. After ALL the corresponding
interval was 20 years.
SPNs. Among survivors assigned to NCSI Levels 1, 2 and 3 the
cumulative risks by 25 years from diagnosis (20 years for ALL) were
o1%, between 1% and 4%, and between 2% and 13%, respectively
(Supplementary Appendix 2). The corresponding SIRs wereo2-fold
expected, between 2 and 5-fold expected, and between 3 and 17-fold
expected, respectively. Among survivors of each specific cancer, both
cumulative and excess risks increased with increased NCSI Level, but
the risks varied strongly with cancer type.
Fatal potentially treatment related non-neoplastic conditions.
Among survivors assigned to NCSI Levels 1, 2 and 3 the
cumulative risks by 25 years from diagnosis (20 years for ALL)
were o1%, between o1% and 2%, and between 1% and 3%,
respectively. The corresponding SMRs were as expected, between 1
and 6-fold expected, and between 2 and 9-fold expected,
respectively. Again, both cumulative and excess risks increased
with increased NCSI Level after specific cancers, but varied
importantly by cancer type.
Non-fatal potentially treatment related non-neoplastic condi-
tions. The cumulative risks were 5%, between 5% and 12%, and
between 7% and 19% by 25 years from diagnosis (20 years for ALL)
among survivors assigned to NCSI Levels 1, 2 and 3, respectively.
Potential impact of missing treatment information. To assign
individuals to a NCSI Level we needed the treatment information
specified in Figure 1B and C. We have the advantage of the
outcomes relating to SPN and death for the entire cohort
irrespective of whether treatment information is missing or
available. Therefore we can investigate cumulative risks of such
outcomes among those with/without sufficient treatment informa-
tion for risk stratification for evidence of heterogeneity. Similarly
among those who returned questionnaires we can compare the
risks of non-fatal non-neoplastic outcomes between those with/
without sufficient treatment information for risk stratification.
Among the entire cohort of 13 130, 5-year survivors of all
childhood cancer except leukaemia, 8675 (66%) had sufficient
treatment available to assign to Levels 1, 2 or 3. In Supplementary
Appendix 3 we investigate cumulative risk of SPN, death and non-
fatal non-neoplastic outcomes between those with/without suffi-
cient treatment information. In Supplementary Appendix 4 we
undertake a similar investigation in relation to survivors of ALL.
There was no evidence of important impact, except that the
cumulative risk of SPNs among non-leukaemic survivors was
higher among those with sufficient treatment information.
DISCUSSION
This study provides the first large-scale investigation of the long-
term (up to 45 years from diagnosis) risks of serious adverse
health-outcomes associated with a simple risk stratification tool
which is already being used on an increasingly widespread basis
within CCLG Centres throughout the UK. The study has the
additional advantage of being population-based. The levels of
clinical follow-up care proposed for childhood cancer survivors
result from the NCSI (NHS Improvement, 2011a, b) and are a
Table 1. Observed and expected numbers, SIRs and cumulative risks of specific types of subsequent primary neoplasms for
survivors of non-leukaemic childhood cancers assigned to NCSI Levels 1, 2 and 3
LEVEL 1 LEVEL 2 LEVEL 3
Specific types of
second primary
neoplasms Obs Exp SIR (95% CI) Cum. risk (95% CI)a Obs Exp SIR (95% CI) Cum. risk (95% CI)a Obs Exp SIR (95% CI)b Cum. risk (95% CI)a,c
Oral cavity and
pharynx
0 0.4 N/A N/A 7 1.0 7.2 (3.4–15.0) 0.49% (0.19–1.12%) 8 0.9 9.0 (4.5–17.9)* 0.31% (0.13–0.68%)
Digestive and
peritoneum
4 1.8 2.2 (0.8–5.8) 0.53% (0.14–1.54%) 23 4.5 5.1 (3.4–7.7) 1.81% (1.06–2.92%) 38 3.8 10.0 (7.3–13.7)***(***) 2.59% (1.63–3.92%)zz(zzz)
Colorectal 2 1.0 2.0 (0.5–7.9) 0.39% (0.07–1.42%) 13 2.5 5.2 (3.0–9.0) 1.12% (0.56–2.03%) 15 2.1 7.3 (4.4–12.0) 0.90% (0.45–1.63%)
Other digestive 2 0.8 2.5 (0.6–9.8) 0.14% (0.01–0.75%) 10 2.0 5.0 (2.7–9.3) 0.70% (0.28–1.51%) 23 1.7 13.2 (8.8–19.9)**(***) 1.70% (0.91–2.91%)zz(zzz)
Respiratory and
intrathoracic
2 1.0 2.0 (0.5–7.8) 0.38% (0.07–1.43%) 7 2.6 2.7 (1.3–5.6) 0.27% (0.09–0.68%) 9 2.2 4.1 (2.2–7.9) 1.33% (0.53–2.84%)
Bone and articular
cartilage
6 0.2 24.7 (11.1–54.9) 0.39% (0.15–0.88%) 24 0.6 42.6 (28.6–63.6) 0.72% (0.46–1.07%) 42 0.6 65.3 (48.2–88.3)*(**) 1.32% (0.85–1.97%)z(zz)
Melanoma 2 1.2 1.6 (0.4–6.5) 0.22% (0.05–0.76%) 9 2.7 3.3 (1.7–6.3) 0.47% (0.18–1.04%) 8 2.6 3.1 (1.5–6.1) 0.42 (0.17–0.94%)
NMSC 4 2.4 1.7 (0.6–4.5) 0.49% (0.15–1.28%) 41 5.6 7.4 (5.4–10.0) 3.12% (2.04–4.55%) 69 4.8 14.4 (11.4–18.2)***(***) 3.78% (2.63–5.25%)zzz(zzz)
Connective and soft
tissue
1 0.3 3.4 (0.5–23.8) 0.08% (0.01–0.42%) 9 0.7 13.2 (6.9–25.3) 0.42% (0.16–0.94%) 26 0.7 37.0 (25.2–54.3)***(***) 1.66% (0.83–2.98%)zzz(zzz)
Breast 4 4.1 1.0 (0.4–2.6) 0.27% (0.08–0.77%) 16 9.5 1.7 (1.0–2.8) 1.35% (0.70–2.40%) 31 6.3 4.9 (3.4–7.0)***(***) 1.79% (1.08–2.79%)zz(zz)
Thyroid 1 0.4 2.8 (0.4–20.1) 0.32% (0.03–1.70%) 9 0.8 11.9 (6.2–22.9) 0.65% (0.30–1.28%) 18 0.7 24.2 (15.3–38.5)**(**) 0.61% (0.36–1.00%)z(zz)
Genito-urinary 6 4.3 1.4 (0.6–3.1) 1.16% (0.30–3.26%) 20 10.1 2.0 (1.3–3.1) 1.77% (0.92–3.11%) 21 9.2 2.3 (1.5–3.5) 0.91% (0.43–1.76%)
Glioma CNS neoplasm 7 0.8 9.1 (4.4–19.2) 0.65% (0.28–1.35%) 12 1.8 6.8 (3.9–12.0) 0.35% (0.17–0.66%) 29 1.8 16.0 (11.2–23.1)*(*) 1.34% (0.75–2.24%)z
NGCNS neoplasm 3 0.8 3.7 (1.2–11.6) 0.22% (0.04–0.79%) 18 1.8 9.9 (6.3–15.8) 1.27% (0.62–2.34%) 79 1.8 43.9 (35.2–54.7)***(***) 4.36% (3.02–6.06%)zzz(zzz)
Other & unspecified 7 5.0 1.4 (0.7–3.0) 0.41% (0.16–0.93%) 26 11.6 2.2 (1.5–3.3) 1.56% (0.84–2.67%) 15 12.0 1.3 (0.8–2.1) 0.61% (0.26–1.30%)z
Total excluding NMSC 43 20.4 2.1 (1.6–2.9) 4.63% (2.96–6.84%) 180 47.6 3.8 (3.3–4.4) 11.13% (9.06–13.43%) 324 42.7 7.6 (6.8–8.5)***(***) 17.27% (14.62–20.11%)zzz(zzz)
Total excluding
NGCNS
44 19.6 2.3 (1.7–3.0) 4.90% (3.19–7.14%) 203 45.8 4.4 (3.9–5.1) 12.63% (10.48–15.00%) 314 40.9 7.7 (6.9–8.6)***(***) 16.69% (14.14–19.43%)zzz(zzz)
Total excluding both
NMSC and NGCNS
40 19.6 2.0 (1.5–2.8) 4.41% (2.77–6.62%) 162 45.8 3.5 (3.0–4.1) 10.30% (8.32–12.53%) 245 40.9 6.0 (5.3–6.8)***(***) 13.70% (11.31–16.32%)zzz(zzz)
Total 47 22.8 2.1 (1.6–2.8) 5.12% (3.38–7.38%) 221 53.2 4.2 (3.6–4.7) 14.25% (11.88–16.82%) 393 47.5 8.3 (7.5–9.1)***(***) 21.06% (18.16–24.10%)zzz(zzz)
Abbreviations: CI¼ confidence interval; CNS¼ central nervous system; Cum¼ cumulative; Exp¼ expected numbers; N/A¼ not applicable; NGCNS¼Non-glioma CNS tumour; NMSC¼non-
melanoma skin cancer; Obs¼ total observed numbers; SIR¼ standardised incidence ratio.
aThe reported cumulative incidences were at 45 years post diagnosis.
bFrom the test for heterogeneity for the respective SIR across the three different follow-up levels *Po0.05; **Po0.01; ***Po0.001. The parenthesis asterisks are from the test for trend for the
SIRs across the three levels *Po0.05; **Po0.01; ***Po0.001.
cFrom the log-rank test for equality of survivor functions across the three levels zPo0.05; zzPo0.01; zzzPo0.001. The parenthesis asterisks are from the log-rank test for trend of survivor functions
across the three levels zPo0.05; zzPo0.01; zzzPo0.001.
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development of a previously proposed risk stratification tool
(Wallace et al, 2001).
By 45 years from diagnosis, cumulative risks of developing any
SPN, dying of any non-neoplastic cause or being diagnosed with
any potentially treatment-related non-fatal non-neoplastic condi-
tion among survivors assigned to Levels 1, 2 or 3 were 21%, 45%
and 69% (Table 3). Excess risks also increased with increasing
NCSI Levels 1, 2 and 3: for SPNs two-fold, four-fold and eight-fold
expected, respectively; for non-neoplastic deaths two-fold, three-
fold and seven-fold expected, respectively.
The risk stratification tool presented above, or an earlier version
(Wallace et al, 2001), has been investigated in terms of the risks of
adverse health-outcomes associated with Levels 1, 2 and 3 in only
three previous studies, which included in aggregate just over 900
survivors (Absolom et al, 2006; Eiser et al, 2006; Michel et al, 2009;
Edgar et al, 2013). The largest of these studies was undertaken by
Edgar et al (2013) based on 607 (5-year) survivors originally
diagnosed with cancer before aged 19 years between 1971 and 2004
at a single institution in Scotland. These investigators reported that
the prevalence of adverse health-outcomes increased from 12% to
36% to 65% for Levels 1, 2 and 3, respectively. Restricted to
grades X3 in CTCAE version 3 (Cancer Therapy Evaluation
Programme, 2006), the corresponding prevalences were 1%, 11%
and 39%, respectively. This is much lower than observed in
our study and reflects the fact that the percentage of 5-year
survivors with a current age beyond 25 years for Levels 1, 2 and 3
were 7%, 27% and 29%, respectively. The BCCSS is a mature
cohort and the age distributions between the NCSI Levels do
not vary much. From the analysis of all non-fatal non-neoplastic
outcomes, 81%, 79% and 80% of the survivors were aged beyond
25 years for Levels 1, 2 and 3. Childhood cancer survivors
experience elevated risks of adverse health-outcomes into middle
age and beyond, and have an accelerated risk of events over
that normally seen with ageing (Oeffinger et al, 2006; Reulen et al,
2010, 2011; Armstrong et al, 2014; Fidler et al, 2016). In the
current study those assigned to NCSI Levels 1, 2 and 3 were
found to experience an increasing risk of a severe adverse health-
outcome by 45 years from FPN diagnosis—21%, 45% and 69%,
respectively.
The second largest study was based on 198 survivors recruited
from one paediatric and one adult follow-up clinic in England, they
found that Level 3 survivors, as defined by Wallace et al (2001)
reported more short-term symptoms attributable to cancer
treatment (for example, pain, fatigue, breathlessness) than Level
2 survivors, and Level 1 reported none (Absolom et al, 2006; Eiser
et al, 2006). Also Level 3 survivors reported more late effects (for
example, infertility, cardiac dysfunction, second cancers) than
Level 1 or 2 survivors. However only eight survivors were classified
to Level 1 and the survivors were aged only 16–39 years at survey
(Absolom et al, 2006; Eiser et al, 2006).
The final of the three previous studies, including 112, 5-year
childhood cancer survivors aged 18–45 years who were recruited
from a late effects clinic, found that Level 3 survivors, reported
more late effects than survivors classified to Level 2. However the
Table 2. Observed and expected numbers, SMRs and cumulative risks of specific non-neoplastic causes of death (upper half).
Cumulative risks for corresponding specific non-fatal non-neoplastic conditions (lower half) for survivors of non-leukaemic
childhood cancers assigned to NCSI Levels 1, 2 and 3
FATAL
LEVEL 1 LEVEL 2 LEVEL 3
Specific non-neoplastic
condition Obs Exp SMR (95% CI)
Cum. risk (95%
CI)a Obs Exp SMR (95% CI)
Cum. risk (95%
CI)a Obs Exp SMR (95% CI)c Cum. risk (95% CI)a,d
Circulatory 6 3.9 1.6 (0.7–3.5) 0.9% (0.3–2.2%) 36 9.5 3.8 (2.7–5.2) 2.1% (1.4–3.2%) 48 8.8 5.5 (4.1–7.2)zz(zz) 2.8% (1.8–4.3%)**(**)
Cardiac disease 5 2.7 1.8 (0.8–4.4) 0.8% (0.2–2.2%) 24 6.8 3.5 (2.4–5.2) 1.5% (0.8–2.4%) 25 6.4 3.9 (2.7–5.8) 1.4% (0.7–2.5%)
Cerebrovascular
disease
1 0.9 1.2 (0.2–8.3) 0.1% (0.0–0.4%) 9 2.1 4.3 (2.3–8.4) 0.6% (0.2–1.2%) 20 1.9 10.8 (7.0–16.8)zz(zzz) 1.3% (0.6–2.5%)**(**)
Pulmonary 6 1.2 4.9 (2.2–10.8) 1.0% (0.3–3.0%) 13 3.0 4.4 (2.6–7.6) 0.7% (0.3–1.4%) 35 2.9 12.3 (8.8–17.1)zz(zz) 2.5% (1.5–3.9%)**(**)
Gastro-intestinal 1 1.1 0.9 (0.1–6.4) 0.1% (0.0–0.4%) 4 2.6 1.6 (0.6–4.2) 0.3% (0.1–1.1%) 8 2.3 3.4 (1.7–6.9) 0.5% (0.2–1.1%)
Renal 1 0.2 5.0 (0.7–35.1) 0.1% (0.0–0.4%) 2 0.5 4.2 (1.0–16.7) 0.1% (0.0–0.5%) 6 0.4 13.5 (6.1–30.0) 0.2% (0.1–0.6%)
Musclo-skeletal 0 0.1 N/A 0.0% (N/A) 0 0.3 N/A 0.0% (N/A) 2 0.3 7.1 (1.8–28.3) 0.1% (0.0–0.6%)
Neurological 0 1.1 N/A 0.0% (N/A) 10 2.7 3.8 (2.0–7.0) 0.8% (0.3–1.9%) 23 2.8 8.3 (5.5–12.5)zzz(zzz) 1.6% (0.8–2.9%)**(***)
Endocrine 3 0.6 5.5 (1.8–16.9) 0.3% (0.1–0.8%) 3 1.3 2.3 (0.8–7.2) 0.1% (0.0–0.6%) 9 1.3 6.7 (3.5–12.9) 0.4% (0.2–1.0%)
Total above specified
causes
17 8.2 2.1 (1.3–3.3) 2.3% (1.1–4.4%) 68 19.8 3.4 (2.7–4.4) 4.2% (3.0–5.7%) 131 18.8 7.0 (5.9–8.3)zzz(zzz) 8.2% (6.3–10.5%)***(***)
Other non-neoplastic
causesb
6 10.6 0.6 (0.3–1.3) 0.7% (0.3–1.4%) 44 25.7 1.7 (1.3–2.3) 2.2% (1.5–3.2%) 46 28.8 1.6 (1.2–2.1)z 1.7% (1.2–2.3%)*(*)
NON-FATAL
LEVEL 1 LEVEL 2 LEVEL 3
Obs Cum. risk (95% CI)a Obs Cum. risk (95% CI)a Obs Cum. risk (95% CI)a,d
Vision 7 1.3% (0.6–2.9%) 21 1.6% (1.0–2.6%) 52 7.1% (4.7–10.7%)***(***)
Hearing 9 1.3% (0.7–2.5%) 53 4.8% (3.5–6.5%) 69 6.7% (4.6–9.7%)**(***)
Circulatory 6 2.4% (1.0–5.7%) 57 6.8% (4.7–9.9%) 102 12.4% (9.5–16.2%)***(***)
Pulmonary 9 2.4% (1.2–4.7%) 49 6.5% (4.5–9.3%) 61 5.4% (4.0–7.3%)**(***)
Gastro-intestinal 15 3.1% (1.6–5.7%) 36 4.3% (2.9–6.5%) 27 2.4% (1.3–4.3%)
Renal 6 0.8% (0.3–2.0%) 16 1.2% (0.7–2.2%) 36 4.5% (2.4–8.1%)**(**)
Musculo-skeletal 2 1.7% (0.4–7.0%) 27 3.6% (2.2–6.1%) 16 1.8% (0.7–5.1%)*
Neurological 2 0.3% (0.1–1.0%) 18 2.3% (1.2–4.2%) 48 4.1% (2.7–6.4%)***(***)
Endocrine 12 2.9% (1.3–6.5%) 52 4.2% (3.0–5.7%) 101 7.8% (5.7–10.5%)***(***)
For any of the specified conditions 59 13.8% (9.9–19.1%) 278 27.3% (23.7–31.3%) 423 39.9% (35.1–45.0%)***(***)
Abbreviations: CI¼ confidence interval; Cum¼ cumulative; Exp¼ expected numbers; N/A¼ not applicable; Obs¼ total observed numbers; SMR¼ standardised mortality ratio.
aThe reported cumulative incidences were at 45 years post diagnosis.
bThis includes deaths from infections, blood disease, mental disorders, pregnancy and childbirth, external causes and others.
cFrom the test for heterogeneity for the respective SMR across the three different follow-up levels zPo0.05; zzPo0.01; zzzPo0.001. The parenthesis asterisks are from the test for trend for the
respective SMR across the three different follow-up levels zPo0.05; zzPo0.01; zzzPo0.001.
dFrom the log-rank test for equality of survivor functions across the three levels *Po0.05; **Po0.01; ***Po0.001. The parenthesis asterisks are from the log-rank test for trend of survivor
functions across the three levels *Po0.05; **Po0.01; ***Po0.001.
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Level 3 survivors were older than the Level 2 survivors and there
was only one survivor classified to Level 1 (Michel et al, 2009).
Follow-up care proposed by the NCSI for Levels 1 and 2 have
substantially reduced frequencies of hospital attendance compared
with Level 3 (NHS Improvement, 2011a, b; Glaser et al, 2013).
Therefore it was essential to investigate whether those individuals
proposed to be followed-up at Levels 1 or 2 experience an increased
risk of any serious adverse health-outcomes which could
potentially be avoided, or at least diagnosed at an earlier stage,
with appropriate hospital follow-up. Detailed investigation for such
evidence revealed that the NCSI flexible system of adjusting the
level of care depending on existing morbidities is unlikely to lead to
deaths which might be prevented or delayed (data not published
due to the potentially individually identifiable nature of the data).
Strengths of our study include its large-scale and population-
based design; also it benefits from substantially longer follow-up
than available to any related previous study. In addition we have
taken into account all serious adverse health-outcomes, including
both those which were fatal or non-fatal, and so have avoided the
limitation of previous related studies which were based on
survivors alone. The population-based design of our study ensures
that the observed and expected numbers, underlying the SMRs and
SIRs, both relate to the entire population of Britain and avoid the
potential biases relating to hospital-based studies. An additional
strength of our study was that we had sufficient numbers to explore
risk of adverse health outcomes by specific types of childhood
cancer stratified by NCSI Levels of care. Such risk should be of
practical benefit in clinics and for further developing standardised
clinical follow-up guidelines (UK CCSG, 2005; SIGN, 2013; COG,
2013).
The principal weakness of our study relates to the crudeness of
the cancer treatment information and the substantial fraction for
whom treatment information was missing. However when
sufficient numbers were available we have explored risks for
specific FPN types who received cancer treatments of increasing
levels of long-term toxicity by NCSI Levels 1, 2 and 3. Also our
investigation of the potential impact of missing treatment on our
risk estimates was mostly reassuring (Supplementary Appendices 3
and 4) and therefore it is unlikely that missing treatment has
impacted the generalisability of our findings to the British
population of childhood cancer survivors. Classification to NCSI
Level used only limited information in the BCCSS computer
record, before assessing available medical records. On subsequent
detailed examination of their medical records we found that we
inevitably classified some individuals initially to Level 1 or 2, when
they should have been Level 3. However, since we reviewed the
medical records of individuals contributing to each cause of death
which was in excess of expected among Levels 1 and 2 survivors
much of this misclassification was identified by the physicians.
General population rates for England and Wales were used to
generate expected numbers for SIRs and SMRs but excluding
Scotland is unlikely to have important impact.
CONCLUSION
The proposed NCSI risk stratification tool is simple, giving a
considerable advantage in terms of clinical application. However, it
provides clear and strong discrimination between survivors
assigned to the three different levels in terms of their long-term
cumulative risk of serious adverse health-outcomes in an
appropriate rank order. It also provides clear and strong
discrimination between survivors assigned to the three levels in
relation to excess risks. This is reassuring as this tool is already in
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Figure 3. Risks of adverse health events after acute lymphoblastic
leukaemia. (A) Observed and expected risks of any subsequent primary
neoplasm after acute lymphoblastic leukaemia. incl¼ including;
NGCNS¼Non-glioma central nervous system tumours; NMSC¼ non-
melanoma skin cancer; obs¼observed. The cross bars are 95% CI.
Log-rank test for equality of observed risks comparing Levels 2 and 3
yields P¼ 0.2052. (B) Observed and expected risks of any fatal non-
neoplastic event after acute lymphoblastic leukaemia. Log-rank test for
equality of observed risks comparing Levels 2 and 3 yields P¼ 0.0018.
(C) Observed risks of any non-fatal non-neoplastic condition after acute
lymphoblastic leukaemia. Log-rank test for equality of observed risks
comparing Levels 2 and 3 yields P¼ 0.0002.
Table 3. Cumulative risk (excess risk) of specified adverse
health outcomes by 45 years from diagnosis of all childhood
cancers combined except leukaemia for specific NCSI Levels
NCSI Level of Clinical Care
Adverse health outcome 1 2 3
Any subsequent primary neoplasm 5% (2-fold) 14% (4-fold) 21% (8-fold)
Any potentially treatment related
non-neoplastic death
2% (2-fold) 4% (3-fold) 8% (7-fold)
Any potentially treatment related
non-fatal non-neoplastic condition
14% 27% 40%
Overall cumulative risk 21% 45% 69%
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increasingly widespread use within the NHS for childhood cancer
survivors.
As the risk stratification tool provides strong discrimination
between groups of survivors, in terms of their long-term risk of
adverse health outcomes, it is likely to be useful internationally.
Furthermore with such strong discrimination, the survivor strata
identified provide a basis for intervention studies of the various
elements which comprise models of care, with a full economic
evaluation, within a wide variety of health care systems whether
privately or state organised.
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